Beyond Breast Cancer: What Survivors and Previvors Should Know About Gynecologic Cancer Risk

September is Gynecologic Cancer Awareness Month, an opportunity to talk about cancers that do not always receive the attention they deserve.

For women who have already faced breast cancer, as well as for "previvors" who know they carry an inherited cancer risk but have never developed cancer, there are some difficult questions to ask: 

Should I have my ovaries, fallopian tubes, or uterus removed to prevent another cancer?

Although the answer may not be the same for every woman, a history of breast cancer alone does not automatically mean that a hysterectomy or removal of the ovaries is necessary. The decision begins with understanding your individual risk.

🔖 First, Know what Cancers We Are Talking About

First let's start by outlining the major gynecologic cancers. These cancers include ovarian, fallopian tube, primary peritoneal, endometrial (uterine), cervical, vaginal, and vulvar cancer. Amongst these cancers, the risk factors and opportunities for screening are very different.

For breast cancer survivors, ovarian and fallopian tube cancers receive particular attention because certain inherited genetic changes—especially BRCA1 and BRCA2—can increase the risk of both breast and ovarian cancer. Lynch syndrome, another inherited cancer syndrome, can substantially increase the risk of endometrial as well as ovarian cancer.

This distinction matters because having had breast cancer is not, by itself, an indication to remove the uterus and ovaries. Personal genetics, family history, age, reproductive plans, prior treatment, and the specific surgery being considered all matter.

🩻 The Screening Problem: We Still Do Not Have a "Mammogram for the Ovaries"

One of the most important facts women should know is also one of the most frustrating: there is currently no ovarian cancer screening test proven to reduce deaths from ovarian cancer.

A pelvic examination cannot reliably detect early ovarian cancer. A transvaginal ultrasound can visualize the ovaries, and a blood test called CA-125 can sometimes be elevated in ovarian cancer. However, neither test is sufficiently accurate to serve as effective routine screening. Besides some benign conditions can cause abnormal results, while some early ovarian cancers produce normal results. Routine screening of average-risk, asymptomatic women with CA-125 or transvaginal ultrasound has therefore not been shown to reduce mortality and can lead to false alarms and unnecessary procedures.

Even among genetically high-risk women, ovarian cancer surveillance has not been shown to provide the mortality benefit we would want from an effective screening program.

The gap in screening is one reason risk-reducing surgery becomes an important conversation for women at sufficiently high inherited risk.

🧬 Start With Your Genes, Not With the Operating Room

For a breast cancer survivor contemplating preventive gynecologic surgery, one of the most useful questions is: Have I had appropriate hereditary cancer testing—and is that testing still adequate by today's standards?

Genetic testing has expanded considerably beyond BRCA1 and BRCA2. Depending on personal and family history, multigene testing may identify other inherited cancer-predisposition genes. A detailed family history remains important even when genetic testing is negative.

Important clues include breast cancer at a young age, ovarian or pancreatic cancer in relatives, male breast cancer, multiple relatives with breast cancer, combinations of colon and endometrial cancers, and a known cancer-associated pathogenic variant in the family. Both your mother's and father's sides of the family count.

For women whose history suggests possible BRCA-related cancer, validated family-history tools can help determine who should proceed to genetic counseling and testing.

For women tested years ago, it may also be worth reviewing exactly what was tested. An older BRCA-only test is different from a contemporary multigene hereditary cancer panel.

💟 When Removing the Ovaries and Fallopian Tubes May Make Sense

For women with certain high-risk pathogenic variants, preventive surgery can change the equation dramatically.

The operation generally used to prevent hereditary ovarian/fallopian tube cancer is called a risk-reducing bilateral salpingo-oophorectomy (RRSO). It removes both ovaries and both fallopian tubes.

For BRCA1 and BRCA2 carriers, this is a well-established cancer-prevention strategy. Traditional guidance has generally recommended RRSO after childbearing is complete, around ages 35–40 for BRCA1 carriers and around ages 40–45 for BRCA2 carriers, reflecting the later onset of ovarian cancer associated with BRCA2.

Other pathogenic variants may carry different levels of ovarian cancer risk and therefore different recommendations. This is one reason the name of the specific gene matters much more than simply being told that a genetic test was "positive."

However, it is important to know that surgery does not reduce the risk to zero. Even after the ovaries and fallopian tubes are removed, a small residual risk of primary peritoneal cancer remains.

🤔 Is a Hysterectomy Necessary Too?

A hysterectomy removes the uterus. It does not remove the ovaries unless oophorectomy is performed at the same time. Conversely, the ovaries and fallopian tubes can be removed while leaving the uterus in place.

For many BRCA1/2 carriers undergoing RRSO, routine hysterectomy is not automatically required for ovarian cancer prevention. There has been concern about a possible association between BRCA1 and an uncommon aggressive form of uterine cancer, but the magnitude of this risk remains uncertain. Current guidance therefore supports an individualized discussion about the advantages and disadvantages of adding hysterectomy rather than treating it as mandatory.

The situation is different with Lynch syndrome, in which the risk of endometrial cancer can be substantial. For women with Lynch syndrome who have completed childbearing, risk-reducing hysterectomy may be considered, with timing individualized according to the specific gene, family history, and personal circumstances.

There may also be other reasons to consider hysterectomy, such as existing uterine disease. For breast cancer survivors, prior or current treatments and their effects on the uterus may also enter the discussion.

🧩 What Are We Trading for Cancer Risk Reduction?

Preventive surgery should not be reduced to the question, "Will this lower my cancer risk?" A better question is, "How much will it lower my personal risk, and what will I trade for that reduction?"

Before natural menopause, removing both ovaries causes immediate surgical menopause. Consequences can include hot flashes, sleep disruption, vaginal dryness, sexual changes, infertility, bone loss, and longer-term cardiovascular and other health considerations. Hormone therapy can sometimes help women after risk-reducing surgery, but its use requires particular consideration in women with a personal history of breast cancer.

A woman who is 38 and premenopausal faces a different benefit-risk calculation from a 62-year-old woman who is already postmenopausal.

There are also the immediate risks of surgery itself, including bleeding, infection, injury to surrounding organs, anesthesia-related complications, and recovery time.

🖼️ How I Would Frame the Decision

Rather than asking simply, "Should I have everything removed?" consider working through these questions:

• What is my actual inherited risk? Review your breast cancer characteristics. Age at diagnosis, collate a three-generation family history, ancestry when relevant, and genetic testing.
• Do I carry a pathogenic variant associated with ovarian or endometrial cancer? The exact gene—and sometimes the specific family history—can change recommendations.
• What exactly am I trying to prevent? Removing the fallopian tubes and ovaries versus removing the uterus prevent different cancers.
• Is there an effective alternative screening strategy? Unfortunately, for ovarian cancer the answer is currently no; CA-125 and ultrasound are not equivalent to mammography, colonoscopy or PAP smears with HPV screening. 
• What is my risk at my current age? Lifetime risk matters, but so does the risk over the next five or ten years.
• What are the consequences of surgery for me now? Menopausal status, fertility goals, bone and cardiovascular health, sexual health, breast cancer history, and treatment history should all enter the calculation.
• What matters most to me? Some survivors find continued surveillance psychologically manageable. Others experience significant uncertainty after cancer and place greater value on reducing another preventable risk. Neither preference can be captured by a laboratory test.

⚠️ Survivorship Is Not the Same as Previvorship

Cancer survivors and previvors may arrive at the same decision from very different places.

A survivor has already experienced diagnosis, treatment, and the uncertainty that follows cancer. The desire to prevent another cancer can understandably be powerful.

A previvor may carry a pathogenic variant and have watched relatives experience cancer but has never personally developed it. She may be deciding when—or whether—to exchange a future cancer risk for the known consequences of preventive surgery.

A pathogenic variant does not mean cancer is inevitable, while a negative genetic test does not mean risk is always zero. Recent evidence continues to underscore that family history can modify risk even within genetic-testing categories.

📣 Know Your Body, Even When There Is No Screening Test

Due to the absence of an effective ovarian screening test, it is important to pay attention to even subtle symptoms. Persistent abdominal or pelvic bloating, pelvic or abdominal pain or pressure, early fullness with eating, unexplained changes in bowel or bladder habits, or increasing abdominal size deserve evaluation.

Abnormal vaginal bleeding—especially bleeding after menopause—also deserves prompt evaluation. Endometrial cancer often announces itself through abnormal bleeding, which provides an opportunity for earlier diagnosis.

Cervical cancer is different. Fortunately there are effective screening through HPV-based testing and/or cervical cytology according to age and screening history.

🥅 The Goal Is Better-Informed Prevention.

Gynecologic Cancer Awareness Month is an important reminder that prevention is not one-size-fits-all.

For some women at high inherited risk, removing the fallopian tubes and ovaries can be lifesaving risk reduction. For certain hereditary syndromes, adding hysterectomy can also make sense. For other breast cancer survivors, those operations may offer little cancer-prevention benefit relative to their consequences.

The most powerful starting point is therefore not rushing into surgery due to overwhelming fear. It is knowing your history, knowing your genes, understanding what we can—and cannot—reliably screen for, and translating those facts into your own balance of benefits and risks.

So in the long run, for survivors and previvors a more useful question may be:

"What is my risk, what can meaningfully reduce it, and what choice allows me to protect both my future health and my quality of life?"

That is the conversation worth having with your care team this September and beyond.

This article is for education and awareness, and does not constitute individual medical advice. Decisions about genetic testing and risk-reducing surgery should be made with your own care team. Persistent symptoms — and any postmenopausal bleeding — deserve prompt evaluation.